Drug Development Innovation Through Adaptive Trials
Martin Roessner, MS, Corporate Vice President, Biostatistics, PAREXEL
Greg Cable, Senior Director, GDO Biostatistics, Global Head Biostatistics for Observational Research, PAREXEL
Many experts agree that the current state of pharmaceutical drug development is not on a sustainable path forward. The average drug-to-market time has stagnated at 12-years, R&D costs continue to rise, and failure rates are as high as 90%.
To better understand these trends, PAREXEL commissioned the Economist Intelligence Unit (EIU) to assess how four clinical trial innovations – patient centricity, adaptive trials, real-world data and precision medicine – could improve the efficiency, productivity and sustainability of drug development.
In a series on innovations driving drug development of the future, PAREXEL experts provide insights on these solutions, including a recent discussion on patient centric trial designs.
This next podcast explores adaptive trial designs as a key innovation that, when used, can increase the likelihood of drug launch, particularly in oncology trials. Adaptive trials were found to recruit more patients faster, reducing overall trial time by two months. Additionally, drugs developed using innovative trial methods, including adaptive trials, are adopted by payers more widely.
There is also a contributed article related to this podcast, which can be accessed via the link below.